Dynamic changes of bone metastasis predict bone‐predominant status to benefit from radium‐223 dichloride for patients with castration‐resistant prostate cancer

BACKGROUND: To best employ radium‐223 dichloride (Ra‐223) for patients with castration‐resistant prostate cancer (CRPC) and bone metastasis, we investigated the bone‐predominant status in patients treated with Ra‐223. METHODS: We retrospectively evaluated 127 CRPC patients who underwent treatment wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hashimoto, Kohei, Miyoshi, Yasuhide, Shindo, Tetsuya, Hori, Masakazu, Tsuboi, Yasumasa, Kobayashi, Ko, Fukuta, Fumimasa, Tanaka, Toshiaki, Miyamoto, Shintaro, Maehana, Takeshi, Okada, Manabu, Nishiyama, Naotaka, Yanase, Masahiro, Kato, Ryuichi, Hotta, Hiroshi, Kunishima, Yasuharu, Takahashi, Atsushi, Hinotsu, Shiro, Sakata, Koh‐ichi, Kitamura, Hiroshi, Uemura, Hiroji, Masumori, Naoya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666734/
https://www.ncbi.nlm.nih.gov/pubmed/32964674
http://dx.doi.org/10.1002/cam4.3459

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666734/
https://www.ncbi.nlm.nih.gov/pubmed/32964674
http://dx.doi.org/10.1002/cam4.3459

Ejemplares similares